ArticleBritish journal of cancer2012
Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation.
Article in British journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Panel miRNAs are potential diagnostic markers for chronic kidney diseases: a systematic review and meta-analysis.BMC nephrology · 2024Pooled it
- Urine Extracellular Vesicle miRNA Changes Induced by Vicadrostat with/Without Empagliflozin in Patients with Chronic Kidney Disease.International journal of molecular sciences · 2025Trial
- A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer.British journal of cancer · 2021Trial
- Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer.EBioMedicine · 2018Trial
- Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer.British journal of cancer · 2016Trial
- MicroRNAs in veterinary viral diseases: A comprehensive review from molecular mechanisms to clinical translation.Virus research · 2026Review
- miRNA expression profile as a potential tool for discrimination between bacterial and interstitial cystitis.Frontiers in immunology · 2026Article
- Application of microRNA In Situ Hybridization on Long-term Stored Human Formalin-fixed Paraffin-embedded Brain Samples from Psychiatric Patients.Molecular neurobiology · 2025Article
- Unveiling the role of miRNA in laryngeal squamous cell carcinoma progression: a retrospective study.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Article
- The role of human papillomavirus 16 in oral cavity and laryngeal cancers in the United States.Journal of the National Cancer Institute · 2025Article
- Spitting in the wind?-The challenges of RNA sequencing for biomarker discovery from saliva.International journal of legal medicine · 2024Article
- Prognostic effect of programmed cell death ligand 1/programmed cell death 1 expression in cancer stem cells of human oral squamous cell carcinoma.Oncology letters · 2024Article
- Article
- Article
- Prognostic and Predictive Effects of Tumor and Plasma miR-200c-3p in Locally Advanced and Metastatic Breast Cancer.Cancers · 2022Article
- An overview of technologies for MS-based proteomics-centric multi-omics.Expert review of proteomics · 2022Article
- Article
- Real-Time PCR Assays on Formalin-Fixed, Paraffin-Embedded Medulloblastomas.Methods in molecular biology (Clifton, N.J.) · 2022Article
- MicroRNA Profiling of the Tears of Children With Vernal Keratoconjunctivitis.Frontiers in genetics · 2022Article
- Blood-Based miRNA Biomarkers as Correlates of Brain-Based miRNA Expression.Frontiers in molecular neuroscience · 2022Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAs degradation of formalin-fixed paraffin-embedded (FFPE) samples limits the ability to profile mRNA expression, we explored factors predicting the success of mRNA expression profiling of FFPE material and investigated an approach to overcome the limitation.
methodsBladder (n=140, stored 3-8 years) and cervix (n=160, stored 8-23 years) carcinoma FFPE samples were hybridised to Affymetrix Exon 1.0ST arrays. Percentage detection above background (%DABG) measured technical success. Biological signal was assessed by distinguishing cervix squamous cell carcinoma (SCC) and adenocarcinoma (AC) using a gene signature. As miR-205 had been identified as a marker of SCC, precursor mir-205 was measured by Exon array and mature miR-205 by qRT-PCR. Genome-wide microRNA (miRNA) expression (Affymetrix miRNA v2.0 arrays) was compared in eight newer FFPE samples with biological signal and eight older samples without.
resultsRNA quality controls (QCs) (e.g., RNA integrity (RIN) number) failed to predict profiling success, but sample age correlated with %DABG in bladder (R=-0.30, P<0.01) and cervix (R=-0.69, P<0.01). Biological signal was lost in older samples and neither a signature nor precursor mir-205 separated samples by histology. miR-205 qRT-PCR discriminated SCC from AC, validated by miRNA profiling (26-fold higher in SCC; P=1.10 × 10(-5)). Genome-wide miRNA (R=0.95) and small nucleolar RNA (R=0.97) expression correlated well in the eight newer vs older FFPE samples and better than mRNA expression (R=0.72).
conclusionSample age is the best predictor of successful mRNA profiling of FFPE material, and miRNA profiling overcomes the limitation of age and copes well with older samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.